Clinical Trial of Topical ABL01 Treatment of Onychomycosis

This clinical trial seeks to investigate if an experimental medical device, ABL01, can be used to treat onychomycosis. In a 1-year trial the effectiveness of ABL01 will be tested against placebo in 70 study subjects with onychomycosis of the big toe nail. The endpoint of the trial is clinical improvement and cure at the 6 and 12 month time-point.

The purpose of this clinical trial is to determine the safety and effectiveness of the medical device ABL01. The intended use of ABL01 is to reduce and treat onychomycosis, fungal nail infection. ABL01 is a solution intended to be topically administered weekly to infected nails. The trial is designed as a double blinded randomized placebo controlled clinical trial. The trial involves 70 study subjects, half of which will receive ABL01 and the other half placebo. The inclusion criteria for study subjects are adult men and women that present with distal lateral subungual onychomycosis (DSU) on the big toe nails. Furthermore, the extent of DSU should not involve more than half of the area of the nail. The study subjects will themselves apply the study solution weekly to the treated nail. The trial will run for 6 months with a possible extension to maximum 12 months. There will be a total of 4 study visits at baseline, 3, 6 and 12 months to follow up the progress of the trial. The primary objective of the trial is to determine if ABL01 treatment are able to reduce and treat onychomycosis. Secondary objectives are to collect safety data, determine if the ABL01 are perceived as easy to use and assess long term effects of the treatment. The endpoint of the trial is reduction in clinical signs or complete cure of onychomycosis at the 6- or 12-month time-point.

Study subjects are randomly assigned to treatment or placebo groups by a predetermined algoritm using sealed envelopes.

Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.

Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.

Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 40% reduction in infected area at the 6 month time period.

Subject reported safety data in combination with reported adverse events and adverse device effects related to the topical administration of ABL01.

Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 80% reduction in infected area at the 12 month time period.

Inclusion Criteria: Provision of written informed consent Men and women above age 18 weighing over 40 kg Present with distal lateral subungual onychomycosis of any of the big toe nails The onychomycosis should involve less than 50 % of the nail bed and may not have reached the cuticle Exclusion Criteria: Unable to come for study visits Known allergy to any of the components in ABL01 Not willing to participate in the trial or not able to understand the content of the trial Present with proximal subungual onychomycosis or superficial onychomycosis. Present with distal lateral subungual onychomycosis of other nails than the big toe. More than 50 % of the nailbed affected by onychomycosis or the cuticles infected Known conditions (like psoriasis) that cause abnormal nail appearance Nail damage caused by trauma, pressure or other mechanical reasons Currently on immunosuppressive therapy Showing signs of poor peripheral blood circulation Used another topical antifungal treatment within 1 month of screening Used a systemic antifungal treatment within 3 months of screening Participated in any other clinical onychomycosis trial in the previous 3 months